- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01024842
Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART
HIV-CORE 001 - A Randomised Placebo-controlled Study to Evaluate the Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVconsv, Delivered by Intramuscular Needle Injection to HIV-1 Seropositive Adult Subjects Receiving Antiretroviral Therapy (ART).
In this study, the novel vaccine candidate, MVA.HIVconsv, will be tested for safety, tolerability and immunogenicity in HIV-1-seropositive subjects receiving effective antiretroviral therapy.
MVA.HIVconsv will be tested as a single vaccine modality, as a prelude to testing in a heterologous viral vector boost regimen which will include a replication-defective simian adenovirus expressing the same immunogen.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Oxon
-
Oxford, Oxon, Regno Unito, OX3 7LJ
- Oxford Genitourinary Medicine
-
-
Oxons
-
Oxford, Oxons, Regno Unito, OX3 9DS
- Weatherall Institute of Molecular Medicine
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female, aged 18-60 years
- Confirmed HIV-1 seropositive
- Willing and able to give written informed consent for participation in the study
- Treated continuously with a combination of 3 or more antiretroviral agents for the preceding 12 months
- Willing and able to adhere to an effective ART regimen for the duration of the study (switching from current regimen is allowed if for reasons of tolerability or toxicity)
- CD4 cell count > 350 cells/μl at screening and at the preceding clinic visit
- Plasma viral load < 50 copies / ml at screening and at the preceding clinic visit
- No new AIDS-defining diagnosis or progression of HIV-related disease in the preceding 6/12 months
Haematological and biochemical laboratory parameters as follows:
- Haemoglobin > 10g/dl
- Platelets > 100,000/μl
- ALT ≤ 2.5 x ULN
- Creatinine ≤ 1.3 x ULN
- Serology: negative for hepatitis B surface antigen OR HbsAg positive with HBV DNA < 1000 copies/ml; negative for hepatitis C antibodies OR confirmed clearance of HCV infection (spontaneous or following treatment); negative syphilis serology or documented adequate treatment of syphilis if positive EIA IgG or TPHA
- Available for follow up for duration of study (screening + 38 weeks) and willing to comply with the protocol requirements
- Women of child-bearing age must not be pregnant, planning a pregnancy or breast-feeding. Sexually active women must be willing to use an approved method of contraception from screening until 4 months after the third immunisation. Sexually active men in heterosexual relationships must be willing to use an approved method of contraception with their partners from screening until 4 months after the third immunisation.
Exclusion Criteria:
- Confirmed HIV-2 seropositive
- Positive pregnancy test
- Participation in another clinical trial within 12 weeks of study entry
- History of autoimmune disease other than HIV-related auto-immune disease which has resolved with ART
- History or clinical manifestations of any physical or psychiatric disorder which could impair the subject's ability to complete the study
- History of anaphylaxis or severe adverse reaction to vaccines
- History of alcohol or drug dependency which could, in the opinion of the investigators, impair the subject's ability to complete the study
- Previous immunisation with a recombinant MVA vaccine
- Immunisation with any experimental immunogens within 6 months of study entry
- Receipt of blood products or immunoglobulins within 6 months of study entry
- Treatment for cancer or lymphoproliferative disease within 1 year of study entry
- Receipt of vaccines other than Hepatitis B vaccine within 2 weeks of study entry or planned receipt within 2 weeks of vaccination
- Any other prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study
- Current or recent use (within last 3 months) of interferon or systemic corticosteroids or other immunosuppressive agents
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Low dose vaccinees
Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu.
|
Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu at week 0, 4 and 12.
|
Sperimentale: High dose vaccinees
Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu.
|
Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu at week 0, 4 and 12.
|
Comparatore placebo: Low dose placebo
Individuals will receive three intramuscular injections of low dose placebo
|
Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
|
Comparatore placebo: High dose placebo
Individuals will receive three intramuscular injections of high dose placebo
|
Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
The proportion of volunteers who develop a grade 3 or 4 local or systemic reactions
Lasso di tempo: Actively collected data throughout the study until 6 months after the last vaccination
|
Actively collected data throughout the study until 6 months after the last vaccination
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
A descriptive summary of grade 3 or 4 local and systemic events, including laboratory abnormalities
Lasso di tempo: Actively collected data throughout the study until 6 months after the last vaccination
|
Actively collected data throughout the study until 6 months after the last vaccination
|
A descriptive summary of serious adverse events, including laboratory abnormalities
Lasso di tempo: Actively collected data throughout the study until 6 months after the last vaccination
|
Actively collected data throughout the study until 6 months after the last vaccination
|
The proportion of volunteers who develop CD8+ T cell responses to a new HIV-1 epitope, as determined by IFN-γ ELISPOT assay
Lasso di tempo: Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
The proportion of volunteers in whom the magnitude of CD8+ T cell responses to HIVconsv peptides increases by ≥ 3-fold, as determined by IFN-γ ELISPOT assay
Lasso di tempo: Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Evaluation of the effect of MVA.HIVconsv vaccinations on viral suppressive capacity of CD8+ T cells in vitro, using a novel flow cytometric assay
Lasso di tempo: Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Magnitude and phenotype, including but not limited to activation status, of HIV-1-specific CD8+ T cell populations identified by tetramer staining before and after vaccination, in selected volunteers with appropriate HLA class I alleles.
Lasso di tempo: Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
PBMC will be stored for other exploratory assays to characterise vaccine-expanded T cell populations such as IL-10 secretion and CFSE proliferation assays.
Lasso di tempo: Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Serum and plasma will be stored for investigation of binding and neutralising antibodies to vaccinia and of pro-inflammatory cytokines.
Lasso di tempo: Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Screen (≤ day -28); Day 0; Day 14; Day 28; Day 42; Day 56; Day 84; Day 112; Day 182; Final visit (day 266 / early termination)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Andrew McMichael, University of Oxford
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- HIV-CORE 001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su HIV-1
-
Helios SaludViiV HealthcareSconosciutoHIV | Infezione da HIV-1Argentina
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... e altri collaboratoriCompletatoHIV-1Burkina Faso, Zambia
-
Hospital Universitari Vall d'Hebron Research InstituteGilead SciencesCompletato
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixaCompletato
-
Gilead SciencesCompletato
-
University of AarhusAarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry of Health...Completato
-
Tibotec Pharmaceuticals, IrelandCompletatoHIV-1Stati Uniti, Francia, Spagna, Portogallo, Canada, Regno Unito, Sud Africa, Argentina, Brasile, Porto Rico, Tailandia, Olanda, Romania
-
Tibotec Pharmaceuticals, IrelandCompletatoHIV-1Stati Uniti, Canada, Francia, Belgio, Germania, Spagna, Argentina, Chile, Panama, Brasile, Porto Rico, Tailandia, Messico, Australia
-
Mymetics CorporationInstitut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma B.V.; CEVAC e altri collaboratoriCompletato
-
Janssen Pharmaceutica N.V., BelgiumCompletato
Prove cliniche su MVA.HIVconsv low dose
-
University of OxfordCompletato
-
Hams Hamed AbdelrahmanCompletato
-
Virginia Commonwealth UniversityGuerbetRitiratoDisfunsione dell'arteria coronaria | Danno renale acuto | Intervento coronarico percutaneoStati Uniti
-
National Institute of Diabetes and Digestive and...CompletatoObesità | Perdita di peso | Aumento di peso | Terapia dietetica | Terapia nutrizionaleStati Uniti
-
Cook Research IncorporatedCompletatoAneurismi dell'aorta addominale | Aneurismi iliaci | Aneurismi aortoiliaciStati Uniti, Canada
-
Legacy Health SystemCompletato
-
University of OxfordKarolinska Institutet; University of Nairobi; International AIDS Vaccine Initiative e altri collaboratoriCompletato
-
Université de SherbrookeQuebec Pain Research NetworkCompletatoDolore lombare meccanicoCanada
-
IrsiCaixaHospital Clinic of Barcelona; University of Oxford; Germans Trias i Pujol Hospital e altri collaboratoriCompletato
-
Unity Health TorontoReclutamento